7News Just In
Danish pharmaceutical company Novo Nordisk is seeking regulatory approval from the TGA for a pill version of the weight loss injection Wegovy, with a decision expected by Christmas. The once-a-day oral medication contains semaglutide, a GLP-1 peptide that suppresses appetite, and would be the first approved oral GLP-1 peptide for chronic weight management in Australia. With two in three Australian adults and one in four school-aged children now overweight or obese, doctors emphasise the need for more treatment options to intervene early and prevent weight-related health conditions. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.
1000 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity 7News Just In-yhteisöön!